Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro-diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, today announced that it has received a notice of allowance from the European Patent Office (EPO) covering the use of Todos’ proprietary Total Biochemical Infrared Analysis (TBIA) platform to identify solid tumors using peripheral blood mononuclear cells (PBMCs). The specific claims being granted cover the use of Fourier Transformed Infrared Analysis (FTIR) spectroscopy and using artificial intelligence on the infrared (IR) data obtained to build algorithms based on the IR spectrum that are predictive of the presence of different types of solid tumors with different tissues of origin. The Company expects the patent to be issued in the coming weeks.
“We are very pleased to see the expansion of the Todos intellectual property portfolio in Europe where Todos is currently in the midst of a pre-commercialization study with partner Orot+ (a division of Orot Luces) for our TM-B1 and TM-B2 breast cancer blood tests,” said Gerald E. Commissiong, President & CEO of Todos Medical. “This particular patent is very significant because it covers the method of using TBIA for the identification of solid tumors. The potential of this technology to eventually be used as a broad screening tool for all cancers, given the low costs of goods sold (COGS) to implement the assay, would represent a sea-change in terms of the ability to do broad cancer screenings for health systems.”
About Todos Medical Ltd.
Todos Medical Ltd. is an in-vitro diagnostic company engaged in the development of blood tests for the early detection of a variety of cancers, and also has initiated the development of blood tests for neurodegenerative disorders such as Alzheimer’s disease through Breakthrough Diagnostics, Inc., its joint venture with Amarantus Bioscience Holdings, Inc. Todos has developed two cancer screening tests based on TBIA (Todos Biochemical Infrared Analyses), a method for cancer screening using peripheral blood analysis. The TBIA screening method is based on the cancer’s influence on the immune system, which triggers biochemical changes in peripheral blood mononuclear cells and plasma. This proprietary and patented method incorporates biochemistry, physics and signal processing. The company’s two cancer screening tests, TM-B1 and TM-B2, have received the CE mark. Todos owns 19.99% of Breakthrough Diagnostics, Inc., a joint venture with Amarantus Bioscience Holdings, Inc. (OTCPK:AMBS) that is developing the LymPro Test®, a blood test for diagnosing Alzheimer’s disease. Todos has exercised its option to acquire Breakthrough, and expects to close on that transaction in the first half of 2020. Todos has also entered into an exclusive option to acquire breast cancer blood testing company Provista Diagnostics, Inc. that is commercializing the Videssa® breast cancer blood test.